Overview

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Status:
Completed

Trial end date:
2017-07-21

Target enrollment:

Participant gender:

Summary

This study is intended to establish the bioequivalence (BE) of single 100 mg doses of glasdegib administered under fasted conditions to healthy volunteers as the ICH formulation compared to the Phase 2 formulation.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Rabeprazole